Core Insights - Merit Medical Systems, Inc. has achieved a significant milestone with SCOUT® Radar Localization being used in 750,000 patients globally, enhancing breast cancer treatment outcomes [1][3][6] Company Overview - Merit Medical, founded in 1987, specializes in the development, manufacture, and distribution of proprietary medical devices for interventional, diagnostic, and therapeutic procedures across various medical fields including cardiology, radiology, oncology, critical care, and endoscopy [8] Product Details - SCOUT® Radar Localization is a wire-free, non-radioactive localization technology that allows for precise surgical removal of abnormal breast tissue, minimizing trauma to surrounding healthy tissue [3][4] - The system utilizes a tiny reflector, about the size of a grain of rice, enabling targeting accuracy within +/- 1 mm, which contributes to more successful surgeries and improved patient care [3] - SCOUT supports various treatment needs, including placement in breast tissue and lymph nodes, and can be utilized pre- or post-neoadjuvant chemotherapy, at the time of biopsy, and for bracketing techniques [4] - The introduction of SCOUT MD™ enhances the localization system with four reflector shapes and distinct radar signals for improved tumor margin mapping and localization of multiple lesions or nodes [5] Market Impact - SCOUT has been referenced in over 100 clinical publications, with nearly 8,500 patients noted, and is utilized in 50 countries, performing more than 500 cases daily, totaling 10,000 cases monthly [6] - Over 1,100 facilities worldwide prefer SCOUT for wire-free localization, indicating strong market adoption and trust in the technology [6] Leadership Perspective - The CEO of Merit Medical expressed pride in the positive impact of SCOUT on patients' lives, emphasizing the company's commitment to supporting individuals with breast cancer beyond just Breast Cancer Awareness Month [7]